G

Grifols SA
D

GRFS

9.07500
USD
-0.06
(-0.66%)
مغلق
حجم التداول
6,966
الربح لكل سهم
1
العائد الربحي
-
P/E
34
حجم السوق
6,174,712,619
أصول ذات صلة
ALNY
ALNY
-4.39
(-1.33%)
325.26 USD
AMGN
AMGN
1.79
(0.60%)
298.52 USD
AZN
AZN
-1.530
(-2.15%)
69.590 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
GSK
GSK
-0.285
(-0.74%)
38.220 USD
ICLR
ICLR
-0.832
(-0.55%)
150.070 USD
NVO
NVO
-0.660
(-0.95%)
69.140 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
SNY
SNY
-0.990
(-2.01%)
48.310 USD
TAK
TAK
-0.105
(-0.68%)
15.335 USD
المزيد
الأخبار المقالات

العنوان: Grifols SA

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.